Timothy Knab, Ph.D.

Science Advisor, Senior Scientist II

Tim joined Metrum in March 2017 after completing his Ph.D. in Chemical Engineering from the University of Pittsburgh where his dissertation was focused on modeling and controlling stress-induced hyperglycemia in critically ill patients. This work included dynamic optimization of models describing glucose-insulin dynamics and the development of model-predictive controllers and state estimators for clinical applications. Tim’s interests include the application of systems biology models to guide decision making in the drug development process and to advance treatment paradigms.

Recent publications by this scientist

Quantitative Systems Pharmacology Modeling of Loncastuximab Tesirine Combined With Mosunetuzumab & Glofitamab Guides Dosing in B-cell Lymphoma

October 1, 2024

Presented at ACCP Annual Meeting 2024, this poster highlights novel research on innovative combination therapies for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). Our study focuses on a physiologically-based pharmacokinetic (PBPK) and quantitative systems pharmacology (QSP) model for Loncastuximab Tesirine in combination with Mosunetuzumab or Glofitama.

Download PDF

Quantitative Systems Pharmacology Model Predicts Combination Activity of CD19-targeted Loncastuximab Tesirine With Epcoritamab in B-cell Lymphoma

October 1, 2024

Presented at ACCP Annual Meeting 2024, this poster highlights a combination QSP model for Loncastuximab Tesirine and Epcoritamab in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), predicting potential anti-tumor synergies in proposed clinical trials.

Download PDF

Quantitative systems pharmacology modeling of loncastuximab tesirine combined with mosunetuzumab and glofitamab helps guide dosing for patients with DLBCL

April 10, 2024

Presented at AACR Annual Meeting 2024. QSP model simulations were used to predict anti-tumor efficacy and guide dosing of the antibody-drug conjugate Loncastuximab tesirine combined with T cell-dependent bispecific antibodies, Mosunetuzumab or Glofitamab for the treatment of B-cell malignancies.

Download PDF